The Hippo pathway and its nuclear effector Yap regulate organ size and cancer formation. While many modulators of Hippo activity have been identified, little is known about the Yap target genes that mediate these growth effects. Here, we show that yap-/-mutant zebrafish exhibit defects in hepatic progenitor potential and liver growth due to impaired glucose transport and nucleotide biosynthesis: transcriptomic and metabolomic analyses reveal that Yap regulates expression of glucose transporter glut1, causing decreased glucose uptake and use for nucleotide biosynthesis in yap-/-mutants, and impaired glucose tolerance in adults. Nucleotide supplementation improved Yap-deficiency phenotypes, indicating functional importance of glucose-fuelled nucleotide biosynthesis. Yapregulated Glut1 expression and glucose uptake are conserved in mammals, suggesting that stimulation of anabolic glucose metabolism is an evolutionarily conserved mechanism by which the Hippo pathway controls organ growth.
Introduction
Control of size at the cell, organ, and organismal level is of fundamental biological importance. The Hippo pathway has recently emerged as a master regulator of organ size control. Hippo pathway signalling is modulated by the integration of environmental cues, including cell-cell contact, cell polarity, G protein-coupled receptor stimulation, mechanical forces and nutrient status (Harvey et al. 2013; Piccolo et al. 2014; Yu et al. 2015) . These stimuli impact the activity of the core Hippo kinase cascade, thereby regulating nuclear localization of the transcriptional co-activators Yap and Taz, which bind to the Tead family of transcription factors to stimulate tissue growth (Harvey et al. 2013; Piccolo et al. 2014) . Prior murine studies have demonstrated that conditional expression of activated Yap in the liver stimulates hepatomegaly and drives tumorigenesis (Camargo et al. 2007; Dong et al. 2007; Zhou et al. 2009; Lu et al. 2010; Yimlamai et al. 2014) . It is now recognized that many oncogenic pathways modulate the Hippo pathway and sustain tumor growth in a Yap-dependent manner (Harvey et al. 2013; Piccolo et al. 2014; Yu et al. 2015) . Much less is known, however, about the requirement for Yap for normal organ development and tissue growth, as global knockout murine models show early embryonic lethality (Morin-Kensicki et al. 2006) . Further, the transcriptional program regulated by Yap to control organ growth is incompletely understood.
Altered cellular metabolism is a hallmark of cancer cells (Hanahan and Weinberg 2011) . Tumor cells exploit metabolic pathways to enhance nutrient uptake and fulfill the biosynthetic requirements needed to increase biomass (Howell et al. 2013; Mayers and Vander Heiden 2015) . Aerobic glycolysis ("Warburg effect") is the best described metabolic change in cancer (Vander Heiden et al. 2009 ).
Recent studies have identified additional mechanisms by which oncogenic pathways reprogram metabolism in cultured cancer cells (Mayers and Vander Heiden 2015) . In addition, we have recently demonstrated that the Hippo pathway effector Yap reprograms glutamine metabolism in vivo to stimulate nucleotide biosynthesis and promote liver growth during development and tumorigenesis (Cox et al. 2016a) . Given the profound impact of Yap on nitrogen metabolism, we hypothesize that Yap enables the cell to change other aspects of its energy metabolism to provide the building blocks for sustained growth during development and organ homeostasis.
In this study, we perform a combination of transcriptomic and metabolomic analyses in yap mutant and transgenic zebrafish to discover that Yap directly stimulates cellular glucose uptake and anabolic glucose utilization for de novo nucleotide biosynthesis through induction of the glucose transporter Glut1. yap-/mutant zebrafish exhibit defects in liver progenitor formation and organ growth during development, and glucose intolerance in adulthood; in contrast, activation of Yap increases liver size. Exposure to GLUT inhibitors suppresses Yapinduced liver growth, whereas nucleotide supplementation alleviates defects in yap-/-mutants. Importantly, regulation of Glut1 and glucose uptake by Yap is conserved in mammals. Together, our findings define Yap as a novel regulator of anabolic glucose metabolism that supports the nucleotide synthesis requirements for organ growth.
Results

Yap is required for optimal liver development
The impact of Yap on organogenesis has been difficult to address in mammalian models due to early embryonic lethality of global Yap knockout mice (Morin-Kensicki et al. 2006) . To investigate the role of Yap in liver development, we examined yap-/-mutant zebrafish embryos ( Fig.S1A) (Miesfeld et al. 2015) , which exhibited multiple developmental abnormalities, ranging from eye pigmentation defects in mildly affected embryos to cardiac edema in more severely affected embryos. In contrast to knockout mice, ~50% of yap-/-mutants survived into adulthood ( Fig.S1B ,C). Liver growth in yap-/-mutants, examined in a fluorescent hepatocyte reporter line (Tg(-2.8fabp10a:CFP-NTR), hereinafter referred to as lf:CFP) (Choi et al. 2014) , was impaired, revealing a ~32% reduction in fluorescent liver area at 3 and 5 days post fertilization (dpf) compared to wild-type (WT) siblings ( Fig.1A,B ; S1D,E). Whole mount in situ hybridization (WISH) analysis confirmed impaired liver growth and demonstrated that growth of other endodermally-derived tissues, such as intestine (intestinal fatty acid binding protein, ifabp) and exocrine pancreas (trypsin), was also impaired by loss of yap (Fig.S1F ). The livers of yap-/-mutant larvae exhibited abnormal histological features (hepatocyte ballooning and sinusoidal widening) with a reduced number of hepatocytes compared to WT ( Fig.1A; S1G) .
Together, these studies demonstrate that yap deficiency impairs liver growth during development.
Yap regulates hepatoblast formation and expansion
To assess whether impaired liver development in yap-deficient embryos could be caused by defects in hepatoblast formation, WISH and qPCR analyses were performed, revealing significantly reduced expression of hepatoblast markers prox1 and hhex in yap-/-embryos at 36 hours post fertilization (hpf) ( Fig.2A,B ).
To further elucidate the developmental impact of Yap, we generated transgenic zebrafish conditionally expressing activated Yap (Tg(hsp70:mcherry-2A-flag-yap1 S87A ), referred to as hs:Yap) or a dominant-negative form of Yap (Tg(hsp70:dnyap-2A-mcherry), referred to as hs:dnYap) under a heat-shock promoter ( Fig.S2A) , enabling the precise temporal regulation of Yap activity.
Detection of mcherry, ctgf and amotl2b by qPCR confirmed effective induction or suppression of Yap target genes upon heat schock ( Fig.S2B ,C,D). Induction of dominant-negative Yap at 24 hpf during liver specification suppressed prox1 and hhex expression at 36 hpf, whereas induction of activated Yap increased prox1 and hhex expression areas ( Fig.2C,D) . Collectively, these data demonstrate that Yap regulates liver progenitor development.
Yap deficient adult zebrafish exhibit liver hypoplasia
Adult yap-/-mutants were easily identifiable from WT fish due to their smaller size ( Fig.S3A ), while dissection revealed smaller livers compared to WT fish ( Fig.3A ). Histological examination demonstrated decreased hepatocyte size of yap-/-hepatocytes ( Fig.3A) . yap-/-mutants had a significantly lower body mass, and further exhibited a 15% reduction in their liver:body mass ratios compared to WT, indicating a specific effect on liver growth independent of, or in addition to, decreased overall body size ( Fig.3B,C) . yap-/-mutant livers also contained reduced glycogen content, as demonstrated by PAS staining, without signs of fibrosis (Masson's Trichrome stain) or endothelial dysfunction (Reticulin stain) ( Fig.S3B ). Given that Yap regulated hepatoblasts during development, we examined how Yap deficiency affected hepatic progenitors in adulthood.
Expression levels of hepatoblast markers hhex and prox1 were reduced by 80% and 55%, respectively, in adult yap-/-mutant liver tissue ( Fig.3D,E) . These studies reveal that yap deficiency in adulthood leads to liver hypoplasia and a reduced pool of hepatic progenitors.
Yap regulates expression of glut1 and glut2
To identify Yap target genes responsible for the observed defects in liver growth, transcriptomic analysis was accomplished by RNAseq in WT and yap-/-mutant embryos at 3 dpf, revealing a large subset of differentially expressed genes ( Fig.4A ). Cross-examination of these datasets was performed with differentially expressed genes in yap-/-;taz-/-double mutant embryos, as well as previously analyzed adult lf:Yap liver tissue (Cox et al. 2016a) , revealing 191 genes that, compared to WT, were significantly downregulated in both yap-/-mutant and yap-/-;taz-/-mutants and induced in lf:Yap embryos ( Fig.S4A ). Among these 191 genes, the glucose transporters glut1 and glut2 were significantly downregulated in yap-/-mutants ( Fig.4B; S4B) . qPCR analysis of yap-/-embryos at 3 dpf confirmed reduction in glut1 and glut2 expression by 84% and 71%, respectively ( Fig.4C ). glut1 and glut2 expression in the heat-shock inducible transgenic lines was significantly reduced upon induction of hs:dnYap at 48 hpf, whereas hs:Yap embryos expressed elevated levels of glut1 and glut2 (Fig.4D ). Finally, glucose transporter expression was suppressed in adult yap-/-mutant liver tissue, while lf:Yap transgenic livers contained 2-3 fold elevated levels of glut1 and glut2 ( Fig.4E ). Together, these experiments demonstrate that Yap is necessary and sufficient to regulate expression of glut1 and glut2.
Yap regulates glucose metabolism and nucleotide biosynthesis
Given that Yap regulates the expression of glucose transporters, we examined the impact of Yap loss on glucose homeostasis in adults, using a glucose tolerance test (GTT). In WT fish, serum glucose levels tripled within 60 mins after intraperitoneal injection of a weight-based glucose dose and normalized by 3-4 hours post injection. These findings indicate a previously unrecognized highly conserved regulation of glucose homeostasis compared to mammals. yap-/mutants at 3 months of age exhibited glucose intolerance, with a ~25% reduced rate of glucose clearance from the blood into peripheral tissue at 120-240 min ( Fig.5A) . Surprisingly, glucose intolerance was markedly exacerbated in aged yap-/-mutant fish at 12 months, where glucose levels did not decrease over 4 hours ( Fig.5B ), indicating metabolic dysregulation in yap-/-mutant fish as they age. Together, these studies suggest that Yap plays an important role in glucose homeostasis.
To further illumniate glucose utilization in yap-/-mutants, polar metabolomics analysis with targeted liquid chromatography -tandem mass spectrometry (LC/MS-MS) via selected reaction monitoring (SRM) was performed ). Hierarchical clustering of metabolite abundance revealed a distinctive metabolic state in yap-/-mutant embryos with significant alterations in steadystate levels of metabolites enriched in glycolysis and de novo nucleotide biosynthesis ( Fig.5C; S5A) . Specifically, yap-/-embryos contained significantly reduced levels of glycolytic intermediates glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), dihydroxyacetone phosphate (DHAP), glyceraldehyde-3phosphate (G3P) and lactate, as well as purine nucleotides deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), adenosine triphosphate (ATP) and guanosine triphosphate (GTP) ( Fig.5D ,E). The decrease of nucleotide triphosphates in yap-/-mutants coincided with an increase in adenosine monophosphate (AMP), guanosine monophosphate (GMP), cytidine monophosphate (CMP) and uridine monophosphate (UMP) ( Fig.S5B) .
Surprisingly, we observed an increase in FBP levels in yap-/-mutant embryos, however, this may be due to allosteric activation of phosphofructokinase (PFK) activity by elevated AMP (Bruser et al. 2012) . Collectively, the decrease in glycolytic intermediates and concomitant increase in nucleotide monophosphates could be a manifestation of energetic stress, caused by abnormal glucose metabolism.
To precisely examine glucose uptake during development, the fluorescent glucose analogue GB2 was visualized in WT and yap-/-mutant larvae in vivo at 5 dpf, revealing suppressed GB2 uptake in yap-/-mutants ( Fig.S5C ,D). To gain greater insight into the fate of glucose in vivo, 13 C relative isotopic enrichment was assessed after exposing WT and yap-/-mutant embryos to [U-13 C 6 ]-glucose from 48-72 hpf. Isotopic enrichment in the glycolytic intermediates G6P, DHAP and G3P was significantly reduced in yap-/-mutants at 72 hpf, supporting a lower rate of glucose uptake, without changes in isotopic enrichment of the downstream TCA cycle intermediates α-ketoglutarate and oxaloacetate ( Fig.5F ; S5E). Importantly, we observed a dramatic reduction in isotopic enrichment of intermediates in de novo biosynthesis of nucleotides in yap-/-mutants such as carbamoyl-L-aspartate, cytosine and guanosine ( Fig.5G ). Collectively, these results illustrate that Yap plays a critical role in the uptake and utilization of glucose for de novo nucleotide synthesis.
Metabolic intervention impacts Yap-driven growth phenotypes
Given the dramatic decrease in nucleotide biosynthesis observed in yap-/mutant embryos, we tested whether nucleoside replacement, achieved through aqueous exposure to a cocktail of deoxynucleosides (NS: deoxyadenosine (dA), deoxyguanosine (dG), deoxycytidine (dC), thymidine (dT)) could rescue aspects of the Yap-deficient phenotype. NS exposure of yap-/-embryos from 1 to 3 dpf significantly decreased the incidence of cardiac edema (observed in severely impacted fraction of yap-/-embryos, Fig.S1A ) from 17.4% to 12.9% ( Fig.6A ) and increased liver size in yap-/-embryos, while demonstrating slightly toxic effects on liver growth in WT embryos ( Fig. S6A,B) . These results indicate a functional link between Yap, glucose transport and nucleotide biosynthesis for normal development and organ growth. To extend our findings beyond the examination of Yap loss on glucose metabolism and liver growth and test whether Yap-driven liver growth was dependent on glut1, we examined lf:Yap larvae, expressing an activated form of Yap in hepatocytes that causes increased liver growth by 5 dpf (Cox et al. 2016a ). Analysis of liver size in WT and lf:Yap larvae following exposure to the irreversible Glut1 inhibitor WZB117 (herein referred to as WZB) Shibuya et al. 2015) from 3-5 dpf demonstrated that hepatomegaly in lf:Yap larvae was effectively suppressed by WZB, whilst having no effect on WT larvae ( Fig.6B ,C). To corroborate these findings, we examined the effect of the competitive Glut inhibitor trehalose (DeBosch et al. 2016) .
Similarly to WZB, trehalose exposure significantly suppressed hepatomegaly in lf:Yap larvae, without affecting WT larvae (Fig.6D ). These studies demonstrate that Yap-driven liver growth conditionally requires GLUT1-mediated uptake of glucose and its utilization for de novo nucleotide biosynthesis, and reveals potential therapeutic targets to inhibit Yap-mediated liver growth during carcinogenesis.
The regulation of glut1 expression and glucose uptake by Yap is evolutionarily conserved in mammals
To determine whether the regulation of glucose transporters and glucose uptake is conserved in mammals, gene expression data from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al. 2012) were analyzed, revealing a strong positive correlation between GLUT1 (SLC2A1) mRNA and either YAP1, AMOTL2 or CYR61 expression ( Fig.7A,B; S7A) . In contrast, no correlation existed between GLUT2 (SLC2A2) or GLUT3 (SLC2A3) and either YAP1, AMOTL2 or CYR61 (Fig.S7A ). Chromatin Immunoprecipitation sequencing (ChIPseq) datasets obtained from LATS2 mutant MSTO211H cancer cells or HA-YAP 5SA expressing HuCCT1 liver cancer cells (Galli et al. 2015 ) revealed a strong TEADbound peak with YAP occupancy within an intragenic enhancer element of the GLUT1 gene ( Fig.7C ). ChIP qPCR analysis verified enrichment of both YAP and TEAD at this enhancer element (Fig.S7B ). The sequence of this enhancer element contains two consensus Tead Binding Site (TBS) motifs adjacent to a consensus AP-1 binding site ( Fig.S7C) , consistent with recent work demonstrating that YAP/TEAD co-occupy chromatin with AP-1 to drive expression of target genes . Furthermore, there was no evidence for binding of YAP or TEAD at the GLUT2 or GLUT3 locus ( Fig.S7D,E) .
Together, these studies suggest that Glut1 is directly regulated by Yap via an intragenic enhancer element.
To determine whether the functional impact of Yap on glucose metabolism is evolutionarily conserved in mice, we used a previously described hepatocytespecific Yap transgenic mouse model (TetONYap) (Yimlamai et al. 2014) , enabling the conditional expression of activated Yap. Administration of doxycycline to TetONYap mice for 10 days leads to the onset of hepatomegaly ( Fig.7D ). Under these conditions, expression of the Yap-target gene Ctgf was elevated 12-fold, whilst expression of Glut1 increased 3-fold ( Fig.S7F,G) .
Corroborating the expression data, a significant increase in the amount of Glut1 at the plasma membrane of hepatocytes was detected by immunohistochemical analysis of TetONYap mouse livers (Fig.7E ). To investigate a potential functional consequence on glucose uptake, we examined 18F-fluorodeoxyglucose ( 18 FDG) uptake in WT and TetONYap mice at 10 days post doxycycline administration, prior to the onset of malignancy, was assessed by PET imaging and scintillation counting of dissected liver tissue. TetONYap liver tissue was FDG-avid, exhibiting a 4-fold increase in 18 FDG uptake ( Fig.7F,G) . Collectively, these studies reveal that the regulation of glucose transporter expression and glucose uptake by Yap is evolutionarily conserved.
Discussion
In the current study, we discovered defects in liver growth and glucose homeostasis in yap-/-mutant zebrafish that persist into adulthood.
Transcriptional profiling revealed that Yap is both necessary and sufficient to regulate expression of glucose transporters glut1 and glut2. Consistent with these changes, metabolic analyses demonstrated that adult yap-/-mutant zebrafish were glucose intolerant, with decreased glucose uptake and utilization in glycolysis and reduced de novo nucleotide biosynthesis. In addition, Glut1 activity was conditionally required for Yap-driven hepatomegaly. The direct regulation of glucose uptake by Yap is conserved in the murine liver, prior to the onset of malignancy. Collectively, our studies provide novel mechanistic insight into Yap-driven tissue growth that may have important therapeutic implications for targeting Yap-dependent growth in cancer. Adult Yap-deficient livers are more susceptible to bile duct ligation-induced liver injury, exhibiting increased hepatocellular necrosis and decreased regeneration of cholangiocytes and hepatocytes (Bai et al. 2012 ). In the current study, we provide novel mechanistic insight into how Yap controls liver size by demonstrating that the observed defects in liver growth and hepatic progenitor potential yap-/-zebrafish are linked to impaired glucose uptake and subsequent use of glucose to support deoxynucleotide synthesis. Importantly, these defects can be partially rescued by repletion of deoxynucleotide pools. Loss of Yap has been shown to impede growth and dysregulate progenitor cell differentiation in a number of different tissues, including the small intestine Barry et al. 2013) , the heart (Xin et al. 2011; Xin et al. 2013) , the kidney (Reginensi et al. 2013; Reginensi et al. 2015) , the mammary gland ) and the neural crest (Wang et al. 2016 ). It will be of great importance in future studies to determine whether perturbations in glucose and nucleotide metabolism contribute to the defects in progenitor cell fate observed in Yap-deficient organs other than the liver.
Role of Yap in stem cell homeostasis and organ development
Regulation of anabolic glucose metabolism in organ growth and cancer
Increased glucose uptake is a hallmark of tumor cells that enables the use of FDG-PET imaging to aid in the detection and prognosis of tumors as well as monitoring their response to therapy (Vander Heiden et al. 2009 ). Clinical studies reveal that FDG uptake in patients with hepatocellular carcinoma (HCC) is correlated with GLUT1 expression . Although FDG-PET scans are routinely used to detect tumors, studies in transgenic mice have found that FDG uptake is not correlated with the rate of tumor growth or cellular proliferation; rather, FDG uptake is oncogene-specific, with Akt1 and Myc-driven tumors exhibiting higher FDG uptake than Wnt, Her2/neu or Ras-driven tumors (Alvarez et al. 2014) . Consequently, it is essential to understand the molecular mechanisms by which tumor cells stimulate glucose uptake. In the current study, we have identified a previously unappreciated role for the Hippo pathway effector Yap in regulating glucose uptake by directly regulating the expression of Glut1 via an intragenic enhancer element. Strikingly, the regulation of glucose uptake by Yap occurs prior to the onset of malignancy. It will be of interest in future studies to examine how the interplay between the Hippo pathway and other oncogenic pathways impact on glucose metabolism in the context of cancer.
The Hippo/Yap pathway acts as a nutrient sensor coordinating metabolism and growth
Recent studies have shed light on the mechanisms by which the Hippo pathway effector Yap is regulated by nutrients in the cellular environment ). The first evidence for this came from the discovery that serum-borne lipids, such as lysophosphatidic acid and sphingosine 1-phosphate, regulate Yap activity (Miller et al. 2012; Yu et al. 2012) . Further work expanded these findings by demonstrating that lipid products of mevalonate and bile metabolism can also promote Yap activation (Anakk et al. 2013; Sorrentino et al. 2014; Wang et al. 2014 Given the extent to which the Hippo pathway senses nutrient status, there is intense interest in identifying whether Yap reprograms metabolic output to enhance tissue growth. We have previously used metabolic and transcriptomic profiling to discover that Yap directly induces glutamine synthetase (glul) and reprograms glutamine metabolism towards de novo nucleotide biosynthesis to fuel liver growth and tumorigenesis (Cox et al. 2016a ). In the current study, we use a combination of approaches to reveal that Yap directly induces the glucose transporters to redirect glucose utilization towards anabolism. The switch to anabolic glucose metabolism is supported by the recent demonstration that Yap is able to repress gluconeogenesis via suppression of PGC1α (Hu et al. 2017 ). In addition to our studies elucidating how Yap regulates glucose transporters, recent reports demonstrate that Yap directly induces the expression of the amino acid transporters SLC38A1 and SLC7A5 to stimulate cell growth Park et al. 2016) . Together, these studies form the basis of an intriguing hypothesis that the Hippo pathway senses nutrients in the environment, whilst Yap mediates metabolic adaptation by co-ordinating biosynthetic output with tissue growth. Under conditions of nutrient deprivation, Yap is inhibited, which suppresses the energy consuming process of tissue growth. However, in nutrient rich conditions, Yap induces the expression of genes that stimulate nutrient uptake and biosynthesis, which facilitates tissue growth.
Although much of the attention on the Hippo pathway effector Yap has focused on its hyperactivation in the context of cancer, few studies have examined the concept that Yap deficiency leads to metabolic dysfunction. Our studies clearly demonstrate that the loss of Yap not only impacts glucose uptake, but more broadly disconnects nutrient sensing by the Hippo pathway, leading to disruption of metabolic homeostasis, as evident from the glucose intolerance in the Yap mutant fish. In line with this notion, Yap is known to regulate a network of genes involved in pancreas development (Cebola et al. 2015) , defects in which could lead to metabolic dysfunction. Furthermore, elegant studies by Ardestani et al. have revealed that the Hippo kinase MST1 is a key regulator of β-cell dysfunction in diabetes (Ardestani et al. 2014) . In this study, the authors showed that MST1 was activated in patients with diabetes and caused β-cell death, which could be rescued by loss of MST1. In light of these findings, we speculate that activation of the Hippo pathway and resulting decrease in Yap activity may play an important role in metabolic dysfunction and diabetes. Yap may influence metabolic homeostasis and disease via two broad mechanisms. First, Yap can impact the development of organs and tissues that have central roles in regulating systemic glucose homeostasis, such as the pancreas or liver. Second, Yap can regulate glucose uptake and metabolism in a cell-autonomous manner.
In summary, we have discovered an evolutionarily conserved role for Yap in the regulation of glucose homeostasis, regulating Glut transporter expression and glucose uptake. Metabolic profiling revealed that Yap regulated the anabolic utilization of glucose for de novo nucleotide biosynthesis. Importantly, we found that glucose uptake was conditionally required for Yap-driven liver growth.
Collectively, these studies provide insights into the mechanism by which Yap reprograms glucose metabolism and thereby identify a metabolic dependency of Yap-driven tissue growth on glucose transport that could be exploited to combat liver cancer.
Materials and Methods
Experimental procedures
Zebrafish husbandry
Zebrafish were maintained according to institutional animal care and use committee (IACUC-BIDMC) protocols. Lines used in this study include WT (AB), Tg(-2.8fabp10:EGFP) as3 , abbreviated lf:GFP (Her et al. 2003) . For this study, we generated Tg(hsp70:mcherry-2A-flag-yap1 S87A ), referred to as hs:Yap and Tg(hsp70:dnyap-2A-mcherry), referred to as hs:dnYap using standard Tol2 transgenesis techniques (Kwan et al. 2007 ). We used plasmids pME-YAPS87A and pME-NLS-YapDN generously provided by Dr. Brian Link (Medical College of Wisconsin, Milwaukee, WI) to generate the heat shock inducible transgenics.
YAPS87A was amplified from pME-YAPS87A using the forward (5'-AAA AGA ATT CAg act aca aag acg atg acg aca agG ATC CGA ACC AGC ACA ACC-3') and reverse (5'-AAA AAG AAT TCC TAT AGC CAG GTT AGA AAG TTC TCC-3') primers to add a Flag-tag (lower case) and EcoRI restriction digest sites (underline). The resulting product was digested with EcoRI-HF (NEB) and cloned into the Tol2 kit vector p3E-2A-pCS2MCS-pA previously digested with EcoRI-HF and calf intestine phosphatase treated (Kwan et al. 2007 ). The resulting plasmid was recombined by Gateway (Life Technologies) recombination with Tol2 kit plasmids pDestTol2pA, p5E-hsp70i and pME-mCherry-nostop to place the heat shock cognate promoter (hsp70i) upstream of the constitutively active YAPS87A Adult founders (F0) were identified by screening their progeny for heat shock inducible mCherry expression. The F1 generation's progeny were then screened for Mendelian inheritance, inducible mCherry expression and brightness, and quantification of mCherry Hippo target gene mRNA expression.
Mouse Lines
Tetracycline-inducible Yap S127A expressing mice were previously described (Camargo et al. 2007; Yimlamai et al. 2014 ). AAV8-TBG-Cre (University of Pennsylvania Vector Core, AV-8-PV1091) was given to 4-to 8-week-old mice retro-orbitally. Male and female mice were used in this study and did not show gender-dimorphic differences. Transgene expression was induced by replacing normal drinking water with 5% sucrose containing doxycycline (1 mg/ml), whereas control (WT) siblings were given 5% sucrose water alone.
Genotyping yap-/-and taz-/-mutants were genotyped as previously described (Miesfeld et al. 2015) . Briefly, genomic DNA was isolated from zebrafish tissue using NaOH (Meeker et al. 2007) . yap was amplified by PCR (forward primer: 5'-AGTCATGGATCCGAACCAGCACAA-3', reverse primer: 5'-GCAGGCTGAAAGTGTGCATTGCC-3') and the 4 bp deletion mutant was assessed for the presence of a TfiI restriction site. Similarly, taz was amplified by PCR (forward primer: 5'-CTCGGCTGAAACTACTTAAGGACG-3', reverse primer:
5'-CTAAACAGTGTGCAGGAATGTCC-3') and the 5 bp deletion mutant was assessed for the presence of a HinfI restriction site.
Heat shock conditions
Embryos were heat shocked by transferring them into pre-warmed (38 °C) egg water and incubating them at 38 °C for 30 min. Genotype was determined by the presence of mCherry fluorescence at 3 hours post heat-shock. Sorted nonfluorescent (WT) siblings were used as controls.
Fluorescence determination of liver size
lf:CFP of lf:GFP larvae were anesthetized with 0.04 mg/ml tricaine methane sulfonate (MS-222) and imaged by fluorescence microscopy using a Zeiss Discovery V8/Axio Cam MRC. Liver area was quantified using FIJI (NIH) as previously described (Schindelin et al. 2012; Weber et al. 2014) .
Histology and immunohistochemistry
Paraformaldehyde (PFA)-fixed larvae, fish were paraffin-embedded, serially sectioned and stained with Hematoxylin and Eosin (H&E), Periodic Acid-Schiff (PAS), Masson's Trichrome or Reticulin stain using standard protocols (Goessling et al. 2008) . Slides were deparaffinized and rehydrated prior to heatinduced antigen retrieval. Glucose transporter 1 (GLUT1) expression was detected using a 1:200 dilution of rabbit α-GLUT1 monoclonal antibody (Abcam, EPR3915) in conjunction with a 1:500 dilution of Alexa Fluor 647-conjugated donkey α-rabbit secondary antibody.
Whole mount in situ hybridization
Zebrafish embryos were fixed in 4% paraformaldehyde (PFA) at the specified stages, and in situ hybridization was performed according to established protocols (http://zfin.org/ZFIN/Methods/ThisseProtocol.html). RNA probes for prox1, hhex, foxa3, gc, ifabp and trypsin were used. Embryos were imaged in glycerol with a Zeiss Discovery V8/Axio Cam MRC with the Axiovision software suite (Carl Zeiss). prox1 expression areas were quantified using FIJI (NIH) as previously described (Schindelin et al. 2012; Weber et al. 2014 ).
qRT-PCR
RNA was isolated from pooled zebrafish larvae or isolated livers using Trizol.
Following DNAse treatment, cDNA was synthesized using the SuperScript III First-Strand Synthesis kit (Life Technologies). qRT-PCR was performed on biological triplicates using an iCycler with iQ SYBR green (BioRad). Gene expression was analyzed with ef1a as the reference gene (see Supplementary   Table of primers) .
RNA transcriptomic analysis
RNA was extracted in Trizol (Life Technologies) WT and yap-/-mutant larvae at 3 dpf using the RNease Mini Kit (Qiagen), according to the manufacturers'
instructions. RNA quality was checked by Agilent Bioanalyzer Sequencing was performed after library construction on an Illumina HiSeq. polyA sequence data were annotated on the ZV9 genomic assembly to identify differentially affected genes (Collins et al. 2012) , as previously described (Cox et al. 2016b ). Gene ontology (GO) and Gene Set Enrichment analysis (GSEA) of biological processes was determined by GO Slim (Gene Ontology Consortium) and GAGE (Luo et al. 2009 ).
Glucose tolerance test (GTT)
The GTT was performed in adult fish according to the methodology outlined by Eames et al (Eames et al. 2010) . Zebrafish were fasted overnight, anaesthetized by brief hypothermic shock and given intraperitoneal injections of glucose (0.5 mg glucose per gram of fish weight) in Cortland salt solution (124.1 mM NaCl, 5.1 mM KCl, 2.9 mM Na 2 HPO 4 , 1.9 mM MgSO 4 7H 2 O, 1.4 mM CaCl 2 2H 2 O, 4%
Polyvinylpyrrolidone and 10,000 U/L Heparin). Following specific periods of recovery, blood was collected following hypothermic shock by tail fin bleeding (Babaei et al. 2013) . The concentration of glucose in collected blood was determined by an Accu-Chek Compact Plus (Roche Diagnostics) glucose meter according to the manufacturer's instructions.
Glucose uptake assays
Glucose uptake was examined by monitoring the uptake of the fluorescent glucose analogue GB2-Cy3, as previously described (Park et al. 2014) . Zebrafish larvae were exposed to 20 µM GB2-Cy3 for 6 hr and imaged by fluorescence microscopy using a Zeiss Discovery V8/Axio Cam MRC. GB2-Cy3 uptake was quantified using FIJI (NIH) as previously described (Schindelin et al. 2012; Weber et al. 2014 ).
Steady-state metabolomics analysis
Polar metabolites were isolated from WT and yap-/-mutant larvae at 3 dpf by methanol extraction. Polar metabolites were isolated and enriched using the methodology outlined by Yuan et al . Metabolite fractions were collected and analyzed by targeted LC-MS/MS via selected reaction monitoring (SRM) with positive/negative ion polarity switching using a 5500 QTRAP hybrid triple quadrupole mass spectrometer (A/B SCIEX). Metabolic pathway enrichment analysis was performed using MetaboAnalyst (Xia et al. 2015) .
Analysis of 13 C enrichment following [ 13 C]-glucose exposure
WT and yap-/-mutant larvae were incubated with 1% [U 13 C 6 ]-glucose at 2dpf for 24 hr. Larvae were subsequently washed and homogenized in methanol.
Metabolites were quantified using SRM on a 5500 QTRAP mass spectrometer using a protocol to detect 13 C-labelled isotopologues of polar metabolites, as previously described .
Chemical exposure
Zebrafish larvae were exposed to WZB-117 (WZB, 10 µM) from 3 to 5 dpf.
Zebrafish embryos were exposed to a cocktail of nucleosides (NS, 25 µM deoxyadenosine, dA, 25 µM deoxyguanosine dG, 25 µM deoxycytidine, dC, 25
µM Thymidine, dT) from 1dpf to 3 dpf. Where necessary, chemicals were dissolved in DMSO. Chemicals were obtained from Sigma-Aldrich (USA).
ChIP analysis
Chromatin Immunoprecipitation was performed as previously described (Galli et al. 2012; Galli et al. 2015 DNA was recovered by reverse crosslinking and purification using QIAquick PCR purification kit (QIAGEN).
PET and scintillation analysis of FDG uptake
Mice were administered doxycycline for 10 days and then fasted overnight prior to PET imaging. Mice received 200 µCi of FDG in 150 ml saline intravenously via the tail vein. Mice were subsequently anesthetized using isoflurane and PET images were acquired 1 hr post injection using a Siemens Focus 120 Scanner.
PET images were reconstructed into a single frame using the 3D ordered subsets expectation maximization (OSEM3D/MAP) algorithm. After imaging, mice were euthanized by CO 2 inhalation and liver tissue was collected, weighed and assessed for radioactivity by scintillation counting.
Statistical analysis
All statistical analysis was performed using GraphPad Prism v7 (GraphPad C.
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Figure 4: Transcriptional profiling reveals that Yap regulates the expression of glut1 and glut2
A) Heatmap of RNAseq analysis illustrating statistically significant differential gene expression between WT and yap-/-mutant larvae at 3 dpf. Blue indicates decreased expression, while red demonstrates increased expression. B) Heatmap analysis of RNAseq data highlights the reduction of glucose transporters (glut1 and glut2) in yap-/-mutant larvae at 3 dpf. C) qPCR analysis of glut1 and glut2 expression in WT and yap-/-mutant larvae at 3 dpf. n>3, *p<0.05, ***p<0.001. D) qPCR analysis of glut1 and glut2 expression in WT, hs:dnYap and hs:Yap transgenic embryos heat shocked at 24 hpf and isolated at 30 hpf. n>3, *p<0.05, **p<0.01, ****p<0.0001, two-sided Student's t-test; values represent the mean ± s.e.m. E) qPCR analysis of glut1 and glut2 expression in liver tissue dissected from WT, yap-/-mutant and lf:Yap transgenic adults. n>3, *p<0.05, **p<0.01, twosided Student's t-test; values represent the mean ± s.e.m. : Metabolic intervention impacts Yap-driven growth phenotypes A) Effect of nucleoside (NS) cocktail treatment from 1-3 dpf on the incidence of cardiac edema in WT and yap-/-mutant larvae. Each point represents the percentage of affected embryos in each independent clutch. n>7, **p<0.01, two-sided Student's t-test; values represent the mean s.e.m. B) Effect of WZB-117 (WZB, 10 µM) treatment from 3-5 dpf in WT and lf:Yap larvae on liver size as determined by fluorescence microscopy at 5 dpf in lf:GFP reporters. Scale bar: 200µm. C) Quantitative analysis of the effect of WZB treatment from 3-5 dpf on liver size as determined by fluorescence microscopy. n>21, ****p<0.0001, two-sided Student's t-test; values represent the mean ± s.e.m. D) Quantitative analysis of the effect of Trehalose (100 µM) treatment from 3-5 dpf on liver size as determined by fluorescence microscopy. n>70, ****p<0.0001, two-sided Student's t-test; values represent the mean ± s.e.m.
